Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas

Cancer Letters

Volumn 238, Issue 1, 2006, Pages 61-68

  Bogusiewicz, Michał ^a   Semczuk, Andrzej ^a   Gogacz, Marek ^a   Skomra, Danuta ^a   Jakowicki, Jerzy A ^a   Rechberger, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

BMI; Endometrial cancer; Leptin; Leptin receptor; PI3 K Akt kinase pathway

Indexed keywords

LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN; PROTEIN; PROTEIN KINASE B; PROTEIN OBR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID TYPE ENDOMETRIUM CARCINOMA; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OBESITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; SCORING SYSTEM; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 33744914835     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.028     Document Type: Article

References (36)

1. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol. Rev. 50 (2001) 443-459
2. Petridou E., Belechri M., Dessypris N., Koukoulomatis P., Diakomanolis E., Spanos E., and Trichopoulos D. Leptin and body mass index in relation to endometrial cancer risk. Ann. Nutr. Metab. 46 (2002) 147-151
3. Somasundar P., McFadden D.W., Hileman S.M., and Vona-Davis L. Leptin is a growth factor in cancer. J. Surg. Res. 116 (2004) 337-349
4. Miturski R., Bogusiewicz M., Josse T., Semczuk A., and Jakowicki J.A. Expression of leptin receptor in endometrial cancer. The 8th world congress on advanced in oncology and 6th international symposium on molecular medicine, Creta Maris, Hersonissos, Crete, Greece. Int. J. Mol. Med. 12 (2003) 396
5. Yuan S.S., Tsai K.B., Chung Y.F., Chan T.F., Yeh Y.T., Tsai L.Y., and Su J.H. Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. Gynecol. Oncol. 92 (2004) 769-775
6. Markowska A., Malendowicz K., and Drews K. The role of leptin in breast cancer. Eur. J. Gynaecol. Oncol. 25 (2004) 192-194
7. Ribeiro R., Lopes C., and Medeiros R. Leptin and prostate: implications for cancer prevention - overview of genetics and molecular interactions. Eur. J. Cancer Prev. 13 (2004) 359-368
8. Levi F., La Vecchia C., Negri E., Parazzini F., and Franceschi S. Body mass at different ages and subsequent endometrial cancer risk. Int. J. Cancer 50 (1992) 567-571
9. Carroll K.K. Obesity as a risk factor for certain types of cancer. Lipids 33 (1998) 1055-1059
10. Bongain A., Isnard V., and Gillet J.Y. Obesity in obstetrics and gynecology. Eur. J. Obstet. Gynecol. Reprod. Biol. 77 (1998) 217-228
11. Zabeau L., Lavens D., Peelman F., Eyckerman F., Vandekerckhove J., and Tavernier J. The ins and outs of leptin receptor activation. Fed. Eur. Biol. Soc. Lett. 546 (2003) 45-50
12. Uotani S., Bjorbaek C., Thornoe J., and Flier J.S. Functional properties of leptin receptor isoforms: internalization and degradation of leptin receptor and ligand-induced receptor downregulation. Diabetes 48 (1999) 279-286
13. Hegyi K., Fulop K., Kovacs K., Toth S., and Falus A. Leptin induced signal transduction pathways. Cell Biol. Int. 28 (2004) 159-169
14. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
15. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl Acad. Sci. USA 95 (1998) 15587-15591
16. Vazquez F., and Sellers W.R. The PTEN suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta 1470 (2000) M21-M35
17. Tashiro H., Blazes M.S., Wu R., Cho K.R., Bose S., Wang S.I., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 (1997) 3935-3940
18. Risinger J.I., Hayes A.K., Berchuck A., and Barrett J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57 (1997) 4736-4738
19. Konopka B., Paszko Z., Janiec-Janowska A., and Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett. 178 (2002) 43-51
20. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst. 92 (2000) 924-930
21. Mikuta J.J. Preoperative evaluation and staging of endometrial cancer. Cancer 76 suppl. (1995) 2041-2043
22. Scully R.E., Bonfiglio T.A., Kurman R.J., Silverberg S.G., and Wilkinson E.J. WHO International Classification of Tumors: Histological typing of Female Genital Tract Tumours. second ed. (1994), Springer, Berlin pp. 14-27
23. Semczuk A., Skomra D., Cybulski M., and Jakowicki J.A. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem. J. 33 (2001) 193-200
24. Nyholm H.C.J., Nielsen A.L., Lyndrup J., Norup P., and Thorpe S.M. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlation with stage and other clinicopathological features. Am. J. Obstet. Gynecol. 167 (1992) 1334-1342
25. Miturski R., Semczuk A., Tomaszewski J., and Jakowicki J. bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Lett. 133 (1998) 63-69
26. Kanamori Y., Kigawa J., Itamochi H., Shimada M., Takahashi M., Kamazawa S., et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 7 (2001) 892-895
27. Cervero A., Horcajadas J.A., Martin J., Pellicer A., and Simon C. The leptin system during human endometrial receptivity and preimplantation development. J. Clin. Endocrinol. Metab. 89 (2004) 2442-2451
28. Cizza G., Romagni P., Lotsikas A., Lam G., Rosenthal N.E., and Chrousos G.P. Plasma leptin in men and women with seasonal affective disorder and in healthy matched controls. Horm. Metab. Res. 37 (2005) 45-48
29. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
30. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. 30 (2004) 193-204
31. Attoub S., Noe V., Pirola L., Bruyneel E., Chastre E., Mareel M., et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase, rho-, and rac-dependent signaling pathways. Fed. Am. Soc. Exp. Biol. J. 14 (2000) 2329-2338
32. Kim D., Dan H.C., Park S., Yang L., Liu Q., Kaneko S., et al. AKT/PKB signaling mechanisms in cancer and chemoresistence. Front. Biosci. 10 (2005) 975-984
33. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
34. Neri L.M., Milani D., Bertolaso L., Stroscio M., Bertagnolo V., and Capitani S. Nuclear translocation of phosphatidylinositol 3-kinase in rat pheochromocytoma PC 12 cells after treatment with nerve growth factor. Cell Mol. Biol. 40 (1994) 619-626
35. Bavelloni A., Santi S., Sirri A., Riccio M., Faenza I., Zini N., et al. Phosphatidylinoositol 3-kinase translocation to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 receptor in human osteosarcoma Saos-2 cells. J. Cell Sci. 112 (1999) 631-640
36. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer 10 (2003) 203-208